Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 109 recruiting now early-phase tilt #27 of 28,707 conditions

HIV: early-phase trial registry

109 of 304 indexed HIV trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #27 of 28,707 conditions by registered trial count.

304 US clinical trials · 109 currently recruiting · #27 of 28,707 conditions by registered trial count

HIV: 304 US clinical trials tracked, 109 recruiting.

HIV is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 24 of these trials.

Enrollment posture brief

Registry condition hiv

OPEN 109 | RECR 36% | LATE 25 | EARLY 64 | RANK #27 | SPON 24

Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)

Acute Myeloid Leukemia51.8%Chronic Pain46%Cardiovascular Diseases44.1%HIV (this)36%COVID-1922.7%
Open-enrollment share among volume-matched conditions near HIV

HIV lists 109 open slots (36% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HIV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HIV recruits in line with its size-band peers.

    109 of 304 indexed trials (35.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of HIV trials is spread across many organizations.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 24 of 304 trials (7.9%). 115 distinct sponsors appear on at least one study for this condition label.

  3. Typical HIV enrolment sits around 100 participants.

    Median target enrolment is 100 among the 304 trials that report a genuine target (sentinel values excluded). 142 of those (46.7%) plan for fewer than 100 participants.

  4. HIV research is mostly interventional.

    252 interventional and 52 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 132Phase 232Phase 312Phase 413

Open and recent trials

304 total, page 4 of 7

COMPLETED NA 1,815 participants

Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya

Sarah Kessler, PhD, MPH

NCT02072603

COMPLETED Phase 3 1,010 participants

Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic

The Miriam Hospital

NCT00947271

COMPLETED Phase 2 1,000 participants

Behavioral Intervention Trial for HIV-infected Injection Drug Users

Centers for Disease Control and Prevention

NCT00146445

COMPLETED Phase 3 901 participants

Training Community Members to Deliver HIV Prevention Programs to Urban Youth

Icahn School of Medicine at Mount Sinai

NCT00859144

COMPLETED NA 900 participants

HOPE Social Media Intervention for HIV Testing and Studying Social Networks

University of California, Irvine

NCT02944877

COMPLETED Phase 3 872 participants

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Gilead Sciences

NCT01780506

COMPLETED NA 856 participants

Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)

Medical College of Wisconsin

NCT01825252

COMPLETED NA 814 participants

Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk

Northeastern University

NCT02493647

COMPLETED Phase 3 707 participants

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Gilead Sciences

NCT01095796

COMPLETED Phase 3 692 participants

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

Tibotec Pharmaceuticals, Ireland

NCT00258557

COMPLETED 600 participants

Study of Recently HIV Infected Men and Transmission Behaviors

University of California, Los Angeles

NCT01201083

COMPLETED NA 583 participants

Community-based Interventions to Increase HIV Testing and HIV Care Utilization

Kaiser Permanente

NCT01867177

COMPLETED NA 478 participants

Integrating HIV and Hepatitis C Screening in an Urban Emergency Department

New York City Health and Hospitals Corporation

NCT03252483

COMPLETED NA 444 participants

Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care

Children's National Research Institute

NCT01775436

COMPLETED NA 410 participants

A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults

University of Minnesota

NCT02704208

COMPLETED NA 400 participants

The Health Access and Recovery Peer Program

Emory University

NCT01725815

COMPLETED Phase 2 400 participants

Online HIV Prevention for Young Male Couples

Northwestern University

NCT03284541

COMPLETED 395 participants

Prospective Cohort Study of HIV and Zika in Infants and Pregnancy

Westat

NCT03263195

COMPLETED NA 378 participants

Connecting Resources for Urban Sexual Health

University of California, San Francisco

NCT02183909

COMPLETED NA 365 participants

VA Video Connect in HIV Care

VA Office of Research and Development

NCT04055207

COMPLETED NA 360 participants

Get Ready And Empowered About Treatment

University of Rochester

NCT02165735

COMPLETED NA 354 participants

Multimedia WORTH With Black Drug-Involved Women on Probation

Columbia University

NCT02391233

COMPLETED Phase 2 352 participants

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

Merck Sharp & Dohme

NCT06045507

COMPLETED 330 participants

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

University of California, Los Angeles

NCT00747539

COMPLETED 330 participants

HIV-related Accelerated Aging of the Airway Epithelium

Weill Medical College of Cornell University

NCT01974219

COMPLETED 326 participants

Quantification of Immune Cells in Women Using Contraception (CHIC II)

University of Pittsburgh

NCT01873170

COMPLETED NA 319 participants

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Yale University

NCT01410123

COMPLETED NA 317 participants

Risk Reduction Intervention for Vulnerable Young Adult Males

Hunter College of City University of New York

NCT01118416

COMPLETED NA 306 participants

Carolina Alcohol and Drug Resources

Duke University

NCT01791179

COMPLETED NA 302 participants

Men Together Making a Difference: Health Promotion for Black Men

University of Pennsylvania

NCT02572414

COMPLETED NA 300 participants

Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons

Butler Hospital

NCT02316184

COMPLETED 284 participants

Functional Imaging Reserve in NeuroHIV

Washington University School of Medicine

NCT03596268

COMPLETED Phase 2 273 participants

Nursing Intervention for HIV Regime Adherence Among People With Serious Mental Illness (SMI)

National Institute of Nursing Research (NINR)

NCT00264823

COMPLETED 256 participants

Efficacy of ART to Interrupt HIV Transmission Networks

University of California, San Diego

NCT02528773

COMPLETED NA 256 participants

Females of African American Legacy Empowering Self (FemAALES)

Charles Drew University of Medicine and Science

NCT02189876

COMPLETED Phase 2 256 participants

Randomized Trial of an HIV Prevention and Relationship Education Program for Young Male Couples

Northwestern University

NCT03186534

COMPLETED NA 254 participants

Innovative Approaches for Minor Consent: Consent 2.0

Indiana University

NCT03242954

COMPLETED NA 242 participants

Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment

Albert Einstein College of Medicine

NCT01376570

COMPLETED NA 230 participants

Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

University of Washington

NCT01161446

COMPLETED NA 229 participants

PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention

ETR Associates

NCT04902820

COMPLETED NA 217 participants

Speed of Processing Training in Adults With HIV

University of Alabama at Birmingham

NCT02758093

COMPLETED NA 216 participants

Treatment Advocacy Intervention for HIV-Positive African Americans

Boston Children's Hospital

NCT01350544

COMPLETED NA 210 participants

Behavioral Interventions to Reduce Heavy Drinking Among MSM in HIV Primary Care

Brown University

NCT02709759

COMPLETED NA 200 participants

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

Rhode Island Hospital

NCT04137094

COMPLETED NA 200 participants

Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites

NYU Langone Health

NCT04207151

COMPLETED NA 200 participants

Providing Online Counseling for Home-Based HIV Testing With Transgender Youth

University of Michigan

NCT03185975

COMPLETED 187 participants

Manhattan HIV/Hepatology Brain Bank

Icahn School of Medicine at Mount Sinai

NCT00300209

COMPLETED NA 180 participants

Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting

Brown University

NCT01328743

COMPLETED Phase 2 177 participants

Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV

University of California, San Francisco

NCT00271856

COMPLETED 175 participants

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00433628

← Previous Page 4 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 32
Phase 2 32
Phase 3 12
Phase 4 13

Named interventions

Most-linked intervention names on HIV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
10 trials
E/C/F/TAF Drug
3 trials
Varenicline Drug
3 trials
Atripla Drug
2 trials
Stribild Drug
2 trials
2GETHER Behavioral
2 trials
Brief Advice Behavioral
2 trials
Neuropsychological testing Behavioral
2 trials

US sites by state

Facility locations filed on HIV trials. A trial with sites in several states counts in each.

California 65 trials
Maryland 50 trials
New York 44 trials
Florida 40 trials
Massachusetts 37 trials
Alabama 22 trials
Pennsylvania 21 trials
North Carolina 21 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HIV page

304 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.